Application of small molecule medicine AN698 / 40746067 in treatment of hyperlipemia and osteoporosis
Through the small molecule drug AN698/40746067, which targets the SDCCAG3 protein, inhibits the lipid differentiation of BMSCs, solves the treatment problems of hyperlipidemia and osteoporosis, and achieves the effect of significantly reducing serum lipid levels and improving drug performance.
Patent Information
- Application Number
- CN202310597570.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-24
AI Technical Summary
The prior art is difficult to effectively treat hyperlipidemia and osteoporosis, especially the correlation between the two has not been clarified, and there are shortcomings in the treatment mechanism of existing drugs.
A small molecule drug AN698/40746067 was developed to inhibit the lipid differentiation of BMSCs by targeting the SDCCAG3 protein, thereby reducing serum lipid levels and treating hyperlipidemia and osteoporosis.
The small molecule drug AN698/40746067 significantly reduces serum lipid levels, effectively treats hyperlipidemia and caused or accompanied obesity and osteoporosis, providing new therapeutic ideas and improving the hydrophilicity and solubility of the drug. Its mechanism of action and metabolic active products in vivo are explored.
Smart Images

Figure BDA0004248908240000021 
Figure BDA0004248908240000031 
Figure BDA0004248908240000081
Abstract
Description
Technical Field
[0001] The invention relates to application of small molecule drug AN698 / 40746067 in treating hyperlipidemia and osteoporosis, belonging to the technical field of biomedicine. Background Art
[0002] Hyperlipidemia (HL) is a type of lipid metabolism disorder characterized by elevated serum triglycerides, total cholesterol, low-density lipoprotein or decreased high-density lipoprotein, and is closely related to metabolic diseases such as atherosclerosis, obesity, and fatty liver. The clinical characteristics of osteoporosis (OP) are: decreased bone mass, destruction of bone microstructure, increased bone fragility, and high incidence of fractures. Surveys show that 63% of osteoporosis patients suffer from hyperlipidemia, and there is a clear correlation between dyslipidemia and osteoporosis.
[0003] The bone marrow is the only area in the body where adipose tissue and bone tissue are in close contact. Both adipocytes and osteoblasts in the bone marrow originate from bone marrow mesenchymal stem cells (BMSCs). BMSCs have good proliferation ability, growth potential and multipotent differentiation stemness. BMSCs can differentiate into preosteoblasts and eventually develop into mature osteoblasts. Mature osteoblasts can synthesize bone matrix and eventually complete the osteogenesis process. In the initial stage of BMSC differentiation into adipocytes, multipotent mesenchymal stem cells participate in the formation of the adipocyte lineage. In the final differentiation stage, preadipocytes become adipocytes and play new functions, including lipid synthesis and storage, and the production of adipocyte-specific proteins. Bone marrow adipose tissue (MAT) occupies 70% of the space in the adult bone marrow cavity and plays an important role in the metabolism of the bone microenvironment. Long-term high-fat diet can lead to excessive expansion of MAT, causing bone marrow adiposity, inhibiting the osteogenic differentiation of BMSCs in the bone marrow cavity and enhancing the adipogenic differentiation, causing bone-fat imbalance and increasing the risk of osteoporosis.
[0004] Small molecule drugs are a class of synthetic drugs with a molecular weight of less than 1000. They often exert biological functions by targeting intracellular proteins. They have the advantages of small side effects, stable performance, and easy synthesis. Compared with biological macromolecules, small molecule drugs have good drug-making properties and pharmacokinetic properties, are easier to pass through the cell membrane, and act efficiently inside the cell. The use of small molecule ligands and their key proteins as therapeutic targets has become a current research hotspot. At present, the drugs used in the clinical treatment of osteoporosis include small molecules and protein antibody macromolecule drugs, such as bisphosphonates and denosumab; while in the treatment of hyperlipidemia, chemical small molecule drugs still occupy a major position, such as statins and fibrates. In 1999, Mundy et al. first discovered that statins, a commonly used cholesterol-lowering drug in clinical practice, have a strong effect on promoting bone formation. It is currently the only drug with a "two-pronged" effect on hyperlipidemia and osteoporosis in clinical practice, but the specific mechanism of action has not yet been clarified. Recently, some scholars have found that statins can inhibit bone marrow obesity caused by castration and alleviate the progression of bone metastasis, suggesting that statins may target MAT to exert their functions. This suggests that targeting the adipogenic differentiation of BMSCs and inhibiting the excessive growth of MAT may be the key to treating hyperlipidemia with osteoporosis.
[0005] Serologically defined colon cancer antigen-3 (Sdccag3), also known as Endosome associated trafficking regulator 1 (Entr1), was first found in the serum of patients with colon cancer and is involved in a variety of life activities in cells, including cell cycle, cell transport, flagella formation and cell apoptosis. The research team's previous studies have found that regulating the expression of Sdccag3 can promote the bone integration of femoral implants in hyperlipidemia rats, suggesting the possibility that Sdccag3 regulates the osteogenic / adipogenic differentiation of BMSCs as a target for the treatment of hyperlipidemia-associated osteoporosis.
[0006] Drug screening is the first step in discovering new drugs. In the past, animal models were used to screen new drugs, which was costly, inefficient, and required a large amount of samples, which was not conducive to drug development. With the rapid development of computer technology, high-throughput screening (HTS) has entered the field of drug development since the 1990s. The HTS technology system integrates pharmacology, molecular and cell biology, computer and automation multidisciplinary theoretical technologies to achieve rapid, efficient, automated and large-scale drug screening. Virtual screening (VS) is the screening of active compounds based on small molecule databases. Based on drug design theory, with the help of computer technology and professional application software, molecular docking operations between small molecule compounds and drug targets are used to quickly select active lead compounds with drugability from tens to millions of molecules, greatly reducing the number of experimental screening compounds, shortening the research cycle, and reducing the cost of drug development. It is reported that the positive rate of virtual screening is 5% to 20%. The number of cases of successful drug design assisted by virtual screening is increasing year by year. Virtual screening has become the most promising drug development tool at present. Summary of the invention
[0007] In view of the deficiencies in the prior art, the present invention provides an application of a small molecule drug AN698 / 40746067 in the treatment of hyperlipidemia and osteoporosis.
[0008] The technical solution of the present invention is as follows:
[0009] The use of small molecule drug AN698 / 40746067 in the preparation of a drug for treating hyperlipidemia, wherein the structural formula of the small molecule drug AN698 / 40746067 is as follows:
[0010]
[0011] Preferably according to the present invention, the small molecule drug AN698 / 40746067 targets the SDCCAG3 protein and reduces serum lipid levels by inhibiting adipogenic differentiation of BMSCs.
[0012] Preferably according to the present invention, the drug for treating hyperlipidemia is composed of the small molecule drug AN698 / 40746067 and pharmaceutically acceptable excipients.
[0013] Preferably according to the present invention, the small molecule drug AN698 / 40746067 is used at a concentration of 0.5 to 1.5 mg / kg.
[0014] The use of small molecule drug AN698 / 40746067 in the preparation of a drug for treating osteoporosis, wherein the structural formula of the small molecule drug AN698 / 40746067 is as follows:
[0015]
[0016] Preferably according to the present invention, the osteoporosis is osteoporosis caused by or associated with hyperlipidemia.
[0017] Preferably according to the present invention, the drug for treating osteoporosis consists of the small molecule drug AN698 / 40746067 and pharmaceutically acceptable excipients.
[0018] Preferably according to the present invention, the small molecule drug AN698 / 40746067 is used at a concentration of 0.5 to 1.5 mg / kg.
[0019] The beneficial effects of the present invention are:
[0020] 1. The present invention is the first to discover that the small molecule drug AN698 / 40746067 has a significant therapeutic effect on hyperlipidemia and osteoporosis. Both in vitro and in vivo verification experiments have shown that the small molecule drug AN698 / 40746067 can significantly reduce serum lipid levels, thereby treating hyperlipidemia, obesity caused by or associated with hyperlipidemia, and osteoporosis.
[0021] 2. The present invention is the first to use SDCCAG3 protein as a target to screen small molecule drugs for the treatment of hyperlipidemia and osteoporosis. The research results show for the first time that the small molecule drug AN698 / 40746067 can inhibit the adipogenic differentiation of BMSCs, thereby reducing serum lipid levels, thereby achieving the effect of treating hyperlipidemia, obesity caused or accompanied by hyperlipidemia, and osteoporosis.
[0022] 3. The use of the small molecule drug AN698 / 40746067 targeting the SDCCAG3 protein provided by the present invention in the preparation of drugs for the treatment of hyperlipidemia and osteoporosis is disclosed for the first time, which provides a new method and new idea for the clinical treatment of hyperlipidemia and osteoporosis drugs. It can improve the hydrophilicity and solubility of the drug through drug structure optimization, increase its in vivo conversion rate, explore its mechanism of action and the active products of metabolism in the body, and provide a new perspective for clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 These are the names and structural formulas of the top 30 small molecule compounds selected based on their affinity to the SDCCAG3 protein.
[0024] Figure 2 The results of qPCR detection of PPAR-γ and FABP4 mRNA levels after 16 small molecule compounds were co-cultured with rat BMSCs in complete high-fat medium for 7 days.
[0025] Figure 3 Oil red O staining (upper) and quantitative analysis (lower) results of small molecule compounds AF-399 / 42018065, AN698 / 40746067 and AN-465 / 42897535 co-cultured with BMSCs in complete high-lipid medium for 14 days.
[0026] Figure 4 Intracellular thermal shift experiment was used to verify the binding of AN698 / 40746067 to the target protein SDCCAG3.
[0027] In the figure: the left figure is the western blot result, the right figure is the quantitative line graph of the western blot result, control is the control group, and AN698 / 40746067 is the experimental group with the addition of small molecule drugs.
[0028] Figure 5 This is the effect of AN698 / 40746067 on the expression level of SDCCAG3 protein.
[0029] In the figure: the left picture is the qRT-PCR result, the right picture is the western blot result, control is the control group, and AN698 / 40746067 is the experimental group with the addition of small molecule drugs.
[0030] Figure 6 These are the CCK8 experimental results of BMSCs after the addition of the small molecule drug AN698 / 40746067 for 1, 5, and 7 days.
[0031] Figure 7 The expression levels of adipogenesis-related indicator genes (top) and adipogenesis-related indicator proteins (bottom) in the experimental group with AN698 / 40746067 added and the high-fat group under high-fat environment.
[0032] Figure 8 The results of Oil Red O staining (left) and quantitative experiment (right) of the normal group, high-fat group and experimental group after 28 days of culture.
[0033] Fig. 9 The expression levels of adipogenesis-related indicator genes (upper) and adipogenesis-related indicator proteins (lower) in the experimental group and adipogenesis group.
[0034] Fig.10 Oil red O staining (left) and quantitative experiment (right) results of the normal group, adipogenic group and experimental group after 28 days of culture.
[0035] Fig.11 Gene expression levels of inflammatory-related factors in the normal group, high-fat group and experimental group after 7 days of culture.
[0036] Fig.12The results of Alizarin red staining (left) and quantitative experiment (right) of the control group and experimental group.
[0037] Fig.13 Serum lipid levels were detected in the normal group (P group) and the high-fat diet group (G group) after 10 weeks of feeding.
[0038] Fig.14 Comparison of body size of the three groups of rats at the end of the experiment (left) and calculation results of Lee's index, an obesity index (right).
[0039] Fig.15 The changes in rat body weight before and after injection of the small molecule drug AN698 / 40746067.
[0040] Fig.16 HE staining results of white adipose tissue around the mesentery of rats in the P, G, and G+ groups.
[0041] Fig.17 These are the results of serum lipid level testing in rats in the P, G, and G+ groups after 16 weeks of feeding.
[0042] Fig.18 These are photos of important organs (heart, liver, spleen, lung, and kidney) of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0043] Fig.19 The net weights of important tissues and organs of rats in P, G, and G+ groups after 16 weeks of feeding.
[0044] Fig. 20 These are the important tissue and organ indexes of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0045] Fig.21 These are the results of HE staining of liver sections of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0046] Fig. 22 These are the results of HE staining of heart, spleen, lung, and kidney tissue sections of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0047] Fig.23 The expression levels of SDCCAG3 protein in bone tissue of rats in P, G, and G+ groups after feeding for 16 weeks.
[0048] Fig.24 The protein expression levels of adipogenesis-related factors PPARγ, C / EBPα and lipid metabolism-related factor LDLR in bone tissue of rats in P, G, and G+ groups after feeding for 16 weeks.
[0049] Fig.25qPCR was used to detect the gene expression levels of adipogenesis-related factors (Pparγ, C / ebpα) and lipid metabolism-related factors (Fabp4, Ldlr, Adipoq) in the proximal tibia bone marrow of rats in the P, G, and G+ groups after feeding for 16 weeks.
[0050] Fig.26 qPCR was used to detect the gene expression levels of inflammatory factors Il-1β and Il-6 in the bone tissue of rats in the P, G, and G+ groups after feeding for 16 weeks.
[0051] Fig. 27 These are the results of HE staining of the distal femur and proximal tibia bone marrow of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0052] Fig.28 The results of immunohistochemical detection of RUNX2 expression in the distal femur and proximal tibia of rats in the P, G, and G+ groups after 16 weeks of feeding.
[0053] Fig.29 Typical Micro-CT images of the distal femur of rats in the P, G, and G+ groups after 16 weeks of feeding (upper) and bone parameter measurement results (lower). DETAILED DESCRIPTION
[0054] The technical scheme of the present invention is further described below in conjunction with the examples and drawings, but the protection scope of the present invention is not limited thereto. The experimental operations involved in the examples are all carried out according to conventional operations unless otherwise specified; the drugs and reagents involved are all common commercially available products unless otherwise specified. Unless otherwise specified, the percentages in the examples are all mass percentages.
[0055] The small molecule drugs in the examples including AN698 / 40746067 were purchased from Specs (https: / / www.specs.net / ).
[0056] High-fat feed was purchased from Jinan CoolJi Biotechnology Co., Ltd.
[0057] Example 1: Small molecule drug screening
[0058] 1. First, download the protein sequence of SDCCAG3 from the NCBI database (NCBI ID: 195540228), apply Swiss-model for homology modeling, remove other small molecules, water molecules, etc. in the model, set the docking pocket, dock with the small molecule compounds in the Specs small molecule library, and select the top 30 small molecule drugs for subsequent screening based on the affinity. The names and structural formulas of the 30 small molecule compounds are as follows: Figure 1 shown.
[0059] 2. Eleven poorly soluble and three unavailable small molecule compounds were excluded, and the remaining 16 small molecule compounds (AK968 / 1157309, AF399 / 42019019, AN806 / 41205070, AK918 / 11939016, AF-399 / 42017853, AF-399 / 42018065, AN698 / 40746067, AF-399 / 13567362, AN-989 / 15133074, AN-989 / 15133060, AN-329 / 4 3385681, AN-465 / 41587276, AK-968 / 41924930, AF-399 / 40634403, AN-758 / 15106208, AN-465 / 42897535, available from Specs) and rat BMSCs were cultured in complete high-fat medium (Pythonbio, catalog number AAPR156-d500) for 7 days, and then RNA was extracted for qRT-PCR to detect the mRNA levels of adipogenesis-related indicators peroxisome proliferator-activated receptor-γ (Pparγ) and fatty acid binding protein 4 (Fabp4). The results are shown in Figure 2 shown.
[0060] Depend on Figure 2 It can be seen that the small molecule compounds AF-399 / 42018065, AN698 / 40746067 and AN-465 / 42897535 can lead to a decrease in the mRNA levels of the screening indicators Pparγ and Fabp4.
[0061] 3. The small molecule compounds AF-399 / 42018065, AN698 / 40746067 and AN-465 / 42897535 were added at 10 - 5 mol / L concentration was dissolved in DMSO and co-cultured with BMSCs in complete high-fat medium. BMSCs cultured in high-fat conditions with equal concentration of DMSO were used as control. After 14 days, they were stained with Oil Red O, and lipid droplets were dissolved with 60% isopropanol after staining for quantitative absorbance analysis. The results are shown in Figure 3 shown.
[0062] Depend on Figure 3 It can be seen that the small molecule compound AN698 / 40746067 has the potential to inhibit the adipogenic differentiation of BMSCs and can be used as a small molecule drug.
[0063] Example 2: Intracellular thermal migration experiment
[0064] Take well-growing BMSCs and count 6×10 6 After the cells were fully mixed, they were equally inoculated into two new culture dishes. After 24 hours of cell adhesion, AN698 / 40746067 (experimental group) and DMSO (control group) were added at a concentration of 10 -6 M's ordinary culture medium (BI, product number C3060-0500), incubate in the incubator for 4 hours; discard the culture medium, rinse with PBS buffer, collect the suspension containing cells after trypsin digestion for 2 minutes, centrifuge at 1000r / min for 5 minutes, discard the supernatant, resuspend the cells in pre-cooled PBS buffer and centrifuge again to discard the supernatant to fully remove the residual culture medium; add 6ml of pre-cooled PBS buffer containing 1× cocktail protease inhibitor to resuspend the cells, and put them into ep tubes at 100μl / tube. The Mastercycler nexus GSX1 gradient PCR instrument was pre-set with 6 temperature gradients (temperature range 30-55°C), and the experimental group and control group cells were heated at different temperatures for 5 minutes, and then taken out after cooling at 4°C for 3 minutes; the cells were repeatedly lysed 3 times in liquid nitrogen freezing-room temperature water bath, centrifuged at 12000r / min and 4°C for 30 minutes, and the supernatant was transferred to a 1.5ml ep tube, which was the obtained protein sample. After the concentration was detected, the subsequent Western blot experiment was performed to detect the Sdccag3 protein content (β-actin was used as an internal reference). The results are shown as follows: Figure 4 shown.
[0065] Depend on Figure 4 It can be seen that the small molecule drug AN698 / 40746067 can bind to the SDCCAG3 protein in cells and improve the thermal stability of the SDCCAG3 protein.
[0066] Experimental Example 3: Effect of AN698 / 40746067 on SDCCAG3 protein expression level
[0067] The experimental group BMSCs and the control group BMSCs were obtained according to the method described in Example 2, and then cultured in complete high-fat medium for 7 days. RNA was extracted for qRT-PCR, and proteins were extracted for western blot experiments according to the method described in Example 2. The results are shown in FIG. Figure 5 shown.
[0068] Depend on Figure 5 It can be seen that the small molecule drug AN698 / 40746067 does not affect the expression of Sdccag3 mRNA transcription level, but can inhibit and reduce the expression of SDCCAG3 protein in BMSCs.
[0069] Experimental Example 4: Effect of AN698 / 40746067 on BMSCs proliferation
[0070] Well-grown BMSCs were selected and seeded into 96-well culture plates at a density of 5000 cells / well. The culture plates were pre-cultured in an incubator at 37°C with 5% carbon dioxide for 24 hours. The old culture medium was discarded and different concentrations (0, 0.01, 10 -3 , 10 -4 , 10 -5 mol / L) was dissolved in ordinary culture medium. The experiment was repeated in 5 duplicate wells in each group. After culturing for 1, 5, and 7 days, the old culture medium was discarded, and the PBS buffer was gently rinsed 1 to 2 times. 100 μL of CCK-8 solution (the volume ratio of CCK-8 stock solution to culture medium was 1:10) was added to each well, and the wells were placed in a 37°C incubator and incubated in the dark for 30 minutes. The absorbance at 450 nm was measured with an enzyme reader. The results are shown in the figure. Figure 6 shown.
[0071] Depend on Figure 6 It can be seen that the small molecule drug AN698 / 40746067 had no significant effect on BMSCs cell proliferation.
[0072] Experimental Example 5: Effect of AN698 / 40746067 on adipogenesis of BMSCs
[0073] 1. Take well-grown BMSCs and add 8×10 4 The cells were seeded into a six-well culture plate at a density of 100 cells / well. After the cells grew to 80%, they were divided into a normal group, an experimental group, and a high-fat group. 2 ml of α-MEM medium containing 10% FBS was added to each well of the normal group, and 2 ml of complete high-fat medium was added to each well of the experimental group and the high-fat group. The small molecule AN698 / 40746067 dissolved in DMSO was added to the experimental group to make the final concentration of 10 -5 mol / l, and the same amount of DMSO was added to the high-fat group.
[0074] The experimental group and the high-fat group were cultured for 7 days, and RNA was extracted for qRT-PCR to detect the levels of adipogenesis-related indicators Pparγ, Fabp4, CCAAT / Enhancer binding proteinα (CCAAT / Enhancer binding proteinα, C / ebpα), adiponectin (Adipoq) and low-density lipoprotein receptor (Ldlr). According to the method described in Example 2, total cell protein was extracted for Western Blot experiments to detect the levels of adipogenesis-related indicators PPARγ, C / EBPα and LDLR. The results are as follows: Figure 7 shown.
[0075] Depend on Figure 7 It can be seen that the expression levels of adipogenesis-related indicator genes Pparγ, Fabp4, C / ebpα, Adipoq and Ldlr in the experimental group were significantly lower than those in the high-fat group cells, and the expression levels of adipogenesis-related indicator proteins PPARγ, C / EBPα and LDLR in the experimental group were significantly lower than those in the high-fat group cells.
[0076] 2. Grouping was the same as in Experiment 1 of this Example. Then, the BMSCs in the normal group, experimental group, and high-fat group were cultured in complete high-fat medium for 28 days. The old medium was discarded and Oil Red O staining was performed. After staining, the lipid droplets were dissolved with 60% isopropanol and absorbance quantitative analysis was performed. The results are shown in Figure 8 shown.
[0077] Depend on Figure 8 It can be seen that Oil Red O staining showed that the lipid droplet formation of BMSCs in the high-fat group was more obvious than that in the normal group, and the lipid droplet formation of BMSCs in the experimental group was weaker than that in the high-fat group. Quantitative analysis showed that the lipid level of BMSCs in the high-fat group was significantly higher than that in the normal group, and the lipid level of BMSCs in the experimental group was significantly lower than that in the high-fat group.
[0078] 3. Weigh 25 mg of insulin powder and dissolve it in 12.5 ml of dilute hydrochloric acid to obtain an insulin solution with a concentration of 57.3 μg / ml; weigh 25 mg of dexamethasone powder and dissolve it in 25 ml of anhydrous ethanol to obtain a dexamethasone solution with a concentration of 1 mg / ml; weigh 35.8 mg of indomethacin powder and dissolve it in 0.5 ml of DMSO to obtain an indomethacin solution with a concentration of 0.2 mol / l; weigh 100 mg of IBMX powder and dissolve it in 2.7 ml of DMSO to obtain an IBMX solution with a concentration of 0.17 mol / l. The liquid was placed in a biosafety cabinet, and 1.4325 ml of insulin solution, 50 μl of dexamethasone solution, 50 μl of indomethacin solution, and 150 μl of IBMX solution were pipetted and dissolved in 20 ml of α-MEM medium, and 10 μl of 1 mol / l sodium hydroxide solution was added to adjust the pH value to 7.0, and the solution was filtered by a bacteria filter. 5 ml of FBS, 0.25 ml of penicillin-streptomycin mixture, and 25 ml of α-MEM medium were added to obtain 50 ml of adipogenesis-induced liquid A, which was stored at 4°C in the dark. 1.4325 ml of insulin solution and 50 μl of dexamethasone solution were pipetted and dissolved in 20 ml of α-MEM medium, and 10 μl of 1 mol / l sodium hydroxide solution was added to adjust the pH value to 7.0, and the solution was filtered by a bacteria filter. 5 ml of FBS, 0.25 ml of penicillin-streptomycin mixture, and 25 ml of α-MEM medium were added to obtain 50 ml of adipogenesis-induced liquid B. Well-grown BMSCs were collected and 8×10 4The cells were seeded into a six-well culture plate at a density of 100 cells / well. After the cells grew to 80%, they were divided into a normal group, an experimental group, and an adipogenic group. The old culture medium was discarded. 2 ml of α-MEM culture medium containing 10% FBS was added to each well of the normal group, and 2 ml of adipogenic induction liquid A was added to each well of the experimental group and the adipogenic group. After 3 days, it was replaced with adipogenic induction liquid B, and after 1 day, it was replaced back to liquid A. The experimental group was then added with small molecules AN698 / 40746067 dissolved in DMSO to a final concentration of 10 -5 mol / l, and an equal amount of DMSO was added to the adipogenic group.
[0079] The experimental group and the adipogenic group were induced to adipogenesis for 14 days, and RNA was extracted for qRT-PCR to detect the levels of adipogenic related indicators Pparγ, Fabp4, C / ebpα, Adipoq and Ldlr. The total cell protein was extracted according to the method described in Example 2 and Western Blot experiments were performed to detect the levels of adipogenic related indicators PPARγ, C / EBPα and LDLR. The results are shown in Fig. 9 shown.
[0080] Depend on Fig. 9 It can be seen that the expression levels of adipogenesis-related indicator genes Pparγ, Fabp4, C / ebpα, Adipoq and Ldlr in the experimental group were significantly lower than those in the adipogenic group cells; the expression levels of adipogenesis-related indicator proteins PPARγ, C / EBPα and LDLR in the experimental group were significantly lower than those in the adipogenic group cells.
[0081] 4. Grouping was the same as in Experiment 3 of this Example. After 14 days of adipogenesis in the normal group, experimental group, and high-fat group, the old culture medium was discarded and Oil Red O staining was performed. After staining, the lipid droplets were dissolved with 60% isopropanol and the absorbance was quantitatively analyzed. The results are shown in Fig.10 shown.
[0082] Depend on Fig.10 It can be seen that Oil Red O staining showed that the lipid droplet formation of BMSCs in the adipogenic group was more obvious than that in the normal group, and the lipid droplet formation of BMSCs in the experimental group was weaker than that in the adipogenic group. Quantitative analysis showed that the lipid level of BMSCs in the adipogenic group was significantly higher than that in the normal group, and the lipid level of BMSCs in the experimental group was significantly lower than that in the adipogenic group.
[0083] Experimental Example 6: Effect of AN698 / 40746067 on the inflammatory response of BMSCs under high-fat environment
[0084] The cells were grouped according to Experiment 1 in Example 5. The normal group and the high-fat group were cultured in a complete high-fat medium for 7 days, and RNA was extracted for qRT-PCR to detect the gene expression levels of tumor necrosis factor α (Tnf-α), transforming growth factor β (Tgf-β), interleukin 1β (Il-1β) and interleukin 6 (Il-6) in the high-fat group. BMSCs in the experimental group and the high-fat group were cultured in a complete high-fat medium for 7 days, and RNA was extracted for qRT-PCR to detect the gene expression levels of Tnf-α, Tgf-β, Il-1β and Il-6 in the high-fat group. The results are as follows: Fig.11 shown.
[0085] Depend on Fig.11 It can be seen that after culturing BMSCs in the normal group, high-fat group and experimental group for 7 days, the gene expression levels of inflammatory-related factors Tnf-α, Tgf-β, Il-1β and Il-6 in the high-fat group were significantly higher than those in the normal group, and the gene expression levels of inflammatory-related factors Tnf-α, Tgf-β, Il-1β and Il-6 in the experimental group were significantly lower than those in the high-fat group.
[0086] Experimental Example 7: Effect of AN698 / 40746067 on BMSCs osteogenesis
[0087] Under light-proof conditions, weigh 0.0039g of dexamethasone in a centrifuge tube, dissolve in 2ml of anhydrous ethanol, add 3ml of common culture medium, filter with a bacteria filter to obtain a 2*10^-3mol / L dexamethasone solution, take 5μl of the solution and dissolve in 5ml of common culture medium to dilute to 2*10^-6mol / L; weigh 0.206g of sodium β-glycerophosphate and 0.005g of vitamin C in a centrifuge tube, dissolve in 5ml of common culture medium, filter with a bacteria filter, take 2.5ml of the solution and 0.25ml of dexamethasone solution, add 47.25ml of common culture medium, and prepare 50ml of osteogenic induction solution. Here, 10% fetal bovine serum is added to the common culture medium.
[0088] Well-grown BMSCs were collected and 8×10 4 The cells were inoculated into a six-well culture plate at a density of 10 cells / well. After the cells grew to 80%, they were divided into an experimental group and a control group. The old culture medium was discarded, and 2 ml of osteogenic induction solution was added to each well. The experimental group was added with DMSO-dissolved small molecule AN698 / 40746067 to a final concentration of 10 -5mol / L, and the control group was added with an equal amount of DMSO. After 28 days of osteogenic induction of BMSCs in the experimental group and the control group, the old culture medium was discarded and the cell mineralized nodules were stained with Alizarin red. After staining, 10% cetylpyridinium chloride was used to dissolve the Alizarin red nodules and the absorbance was quantitatively analyzed. The results are shown in Fig.12 shown.
[0089] Depend on Fig.12 It can be seen that the cell mineralization nodules were stained with alizarin red and showed that both the experimental group and the control group had obvious mineralization nodules, but the cell mineralization nodules in the experimental group treated with AN698 / 40746067 were enhanced compared with those in the control group, and the staining degree of the two groups was different. The quantitative analysis results showed that there was a statistical difference between the experimental group and the control group, and the mineralization nodules in the experimental group were stronger than those in the control group.
[0090] Example 8. Establishment of hyperlipidemia animal model, drug injection, specimen collection and processing
[0091] 1. Fifteen 10-week-old male Wistar rats were randomly divided into three groups, namely, a normal group (P group), a high-fat diet group (G group), and a high-fat diet plus small molecule drug treatment group (G+AN698 / 40746067 group, referred to as G+ group), with 5 rats in each group. The P group was given a normal diet, and the G and G+ groups were uniformly given a high-fat diet during the establishment of the hyperlipidemia rat model. Body weight was recorded every week. After 10 weeks of feeding, blood was collected from the medial canthus vein after fasting and deprivation of water for 16 hours in advance, and serum lipid levels were tested using an automatic biochemical analyzer. The results are as follows Fig.13 And as shown in Table 1.
[0092] Table 1. Serum lipid test results of rats in group P and group G after 10 weeks of feeding (mean ± SD, unit: mmol / L)
[0093]
[0094]
[0095] Depend on Fig.13 As shown in Table 1, the levels of serum total cholesterol (T-CHO), low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) in the Wistar rats in the high-fat diet group (G group) were significantly increased compared with those in the normal group (P group), and the difference was statistically significant (P < 0.05), indicating that the hyperlipidemia model of Wistar rats was successfully established.
[0096] 2. After the hyperlipidemia rat model was successfully established, the normal group (P group) and the high-fat diet group (G group) were raised as usual until 16 weeks. The high-fat diet plus drug group (G+ group) was injected with drugs, specifically: the high-fat diet plus drug group (G+ group) was given a 1 mg / kg intraperitoneal injection of the small molecule drug AN698 / 40746067, once every 3 days, and specimens were collected after 6 weeks. The small molecule drug AN698 / 40746067 was fully dissolved in DMSO to prepare a 10 mg / ml injection stock solution, which was diluted with physiological saline during injection to ensure that the final DMSO concentration was less than 1%.
[0097] When sampling, Wistar rats in the P, G, and G+ groups were injected with an overdose of sodium pentobarbital intraperitoneally to confirm that the heart had stopped beating, and then the body length from the nose tip to the anus of the rats was measured. The skin, subcutaneous tissue, and muscle were cut upward and downward from the xiphoid process of the sternum, and the chest and abdominal cavities were opened. The heart, liver, spleen, lung, kidney, and mesenteric surrounding adipose tissue were bluntly separated. The separated organ tissues were rinsed with physiological saline, and then dried with absorbent paper and placed in a clean culture dish for weighing and photographing. The corresponding organ index was subsequently calculated according to the body weight (calculation method: organ index = net weight of a certain organ (g) / body weight (g) * 100%). The skin and muscles of the legs were cut in turn, and the femur and tibia were separated, and the muscles around the bones were carefully removed. The separated organ tissues were placed in a test tube containing 4% paraformaldehyde for fixation for subsequent experiments. The other half of the separated femur and tibia were placed in liquid nitrogen for rapid freezing for subsequent RNA and protein experiments.
[0098] Example 9: Effect of AN698 / 40746067 treatment on obesity signs in hyperlipidemic rats
[0099] 1. After 16 weeks of feeding according to the method described in Example 8, the weight of rats in group G and group G+ increased significantly compared with group P. The difference in body size among the three groups was obvious, and the Lee's index of rats in group G and group G+ was significantly higher than that in group P ( Fig.14 The calculation formula of the Lee's index is: Lee's index = body weight (g) ^ 1 / 3 * 10 / body length (cm). From the monitoring of body weight, it was observed that after the injection of the small molecule drug AN698 / 40746067 for 11 weeks, the weight gain trend of the G+ group decreased ( Fig.15 ). After treatment with the small molecule drug AN698 / 40746067, the Lee's index of the G+ group was significantly lower than that of the G group, and the difference was statistically significant ( Fig.14 , P<0.05).
[0100] 2. HE staining was performed on the rat mesenteric white adipose tissue obtained in Example 8. The results are as follows: Fig.16 shown.
[0101] Depend on Fig.16 It can be seen that compared with the P group, the diameter of the white fat cells around the mesentery of the rats in the G group and the G+ group increased, and after the treatment of the small molecule drug AN698 / 40746067, the diameter of the fat cells in the G+ group decreased compared with the G group, and was closer to the fat cell morphology of the P group (400×), indicating that the small molecule drug AN698 / 40746067 alleviated the obesity level of rats.
[0102] 3. The results of serum lipid levels in rats in the P, G, and G+ groups after 16 weeks of feeding are as follows Fig.17 shown.
[0103] Depend on Fig.17 It can be seen that after treatment with the small molecule drug AN698 / 40746067, the levels of T-CHO and LDL-C in the serum of the rats in the G+ group were significantly lower than those in the G group, and the difference was statistically significant (P < 0.05). The level of TG showed a downward trend, but did not show a significant statistical difference (P > 0.05). The level of HDL-C increased, and the difference was statistically significant (P < 0.05). This shows that the small molecule drug AN698 / 40746067 can effectively improve the increase in serum lipid levels induced by a high-fat diet, and the effect is more obvious for lipids mainly composed of cholesterol.
[0104] 4. The important organs (heart, liver, spleen, lung, kidney) obtained in Example 8 were weighed, measured and HE-stained for soft tissue sections. The results are as follows: Figures 18 to 20 shown.
[0105] HE staining of soft tissue sections: The soft tissues of each organ obtained in Example 8 were fixed in 4% paraformaldehyde for 12 to 24 hours, and then sliced after washing, gradient alcohol dehydration, xylene transparentization, wax immersion and 65°C paraffin embedding, and the thickness was set to 5 μm. After obtaining each soft tissue paraffin section, the soft tissue section was stained with HE staining using the Solebow HE staining kit (Cat. No.: G1120) according to the instructions. The specific steps are as follows: bake the heart, liver, spleen, lung, kidney and adipose tissue sections to be stained on a slide baker for 1 to 2 hours to melt the paraffin; dewax the sections in xylene in a fume hood, xylene I for 10 minutes → xylene II for 10 minutes; rehydrate in 100%, 95%, 85%, and 75% gradient alcohol, soak for 3 minutes each; soak in distilled water for 2 minutes; after hematoxylin staining for 3 minutes, rinse the staining solution with distilled water; after differentiation with differentiation solution for 3 minutes, gently rinse twice with distilled water, 2 minutes each; stain with eosin for 30 seconds to 1 minute, and quickly rinse the staining solution with distilled water; soak in 75%, 85%, 95%, and 100% alcohol for 2 to 3 seconds each; soak in 100% alcohol II for 1 minute; make xylene I and xylene II transparent for 1 minute each, take out the sections, dry them slightly, and then seal them with neutral gum. The results are shown in Figures 21 to 22.
[0106] Depend on Figures 18 to 22 It can be seen that neither high-fat diet nor small molecule drug AN698 / 40746067 treatment had adverse effects on the tissue cell morphology and organ weight of the heart, spleen, lung and kidney, indicating that the small molecule drug AN698 / 40746067 has no significant acute toxicity to important organs in rats. The rats in group G showed pathological changes of fatty liver. The liver was diffusely enlarged and grayish yellow in color. HE staining of the sections showed that the liver cells were filled with lipid droplet vacuoles of varying sizes, and the normal morphology of the liver lobules disappeared. After treatment with the small molecule drug AN698 / 40746067, the signs of fatty liver in the G+ group were alleviated.
[0107] Example 11: Effect of AN698 / 40746067 treatment on RNA and protein expression levels of adipogenesis, lipid metabolism-related factors and inflammatory factors in bone tissue
[0108] 1. Use Invent's bone tissue total protein extraction kit (catalog number: SA-02-BT) to extract rat bone tissue total protein. The steps are as follows: Cut 50-100 mg of proximal tibia bone tissue and put it into a pre-cooled mortar, add liquid nitrogen in small amounts and multiple times to grind it into powder, and transfer the bone tissue powder to a collection tube containing a filter column; add 50-80 mg of protein extraction powder and 100 μl of lysis buffer, and incubate at room temperature for 5-10 minutes; gently grind with a plastic rod for 2-3 minutes, then add 100 μl of lysis buffer again and grind for 30 seconds to 1 minute; centrifuge at 14000×g at room temperature for 1 minute, discard the filter column, and transfer the supernatant to a new 1.5 ml ep tube to obtain the total bone tissue protein. After obtaining the protein concentration using BCA, Western Blot was used to detect the expression levels of SDCCAG3 protein, PPARγ, C / EBPα and LDLR in bone tissue. The results are as follows Figures 23-24 shown.
[0109] Depend on Fig.23 It can be seen that the SDCCAG3 protein level in the G+ group after treatment with the small molecule drug AN698 / 40746067 was significantly lower than that in the G group (P < 0.05), indicating that the small molecule drug AN698 / 40746067 can effectively inhibit the expression of SDCCAG3 in rats.
[0110] Depend on Fig.24It can be seen that the expression levels of PPARγ and C / EBPα proteins in the G group increased, and the difference was statistically significant (P < 0.05), indicating that the high-fat diet induced enhanced adipogenic differentiation of BMSCs. After treatment with the small molecule drug AN698 / 40746067, the PPARγ and C / EBPα proteins in the G+ group were significantly decreased compared with the G group (P < 0.05), while LDLR showed an upward trend in the G group and a downward trend in the G+ group, but there was no statistical difference (P > 0.05). The above results show that the small molecule drug AN698 / 40746067 can significantly inhibit the progression of bone marrow adipogenesis in hyperlipidemic rats.
[0111] 2. According to Vazyme Fast RNA was extracted from the bone tissue of rats in the P, G, and G+ groups according to the instructions of the EACell / Tissue Total RNAIsolation Kit (Cat. No.: RC101). Specifically, 20 mg of proximal tibia bone tissue was cut into a pre-cooled mortar and immediately added with liquid nitrogen to grind into powder. Add 500 μl Buffer RL1 (beta-mercaptoethanol was added in advance to a final concentration of 1%), blow thoroughly with a pipette, and centrifuge at 12000 rpm at room temperature for 3 minutes. Transfer the supernatant to gDNA-Filter Columns (already placed in the collection tube), and centrifuge at 12000 rpm at room temperature for 2 minutes. Discard the gDNA-Filter Columns and retain the liquid in the collection tube. Add 800 μl Buffer RL2 (with a specified volume of anhydrous ethanol added) to the collection tube and mix gently. Transfer the mixed solution from the previous step to RNAPure Columns (already placed in the collection tube), centrifuge at 12000 rpm at room temperature for 1 minute, and discard the waste liquid. Add 500μl Buffer RW1 to RNAPure Columns, centrifuge at 12000rpm for 1 minute at room temperature, and discard the waste liquid. Add 700μl Buffer RW2 to RNAPure Columns, centrifuge at 12000rpm for 1 minute at room temperature, and discard the waste liquid. Repeat the previous step. Put the RNAPure Columns back into the collection tube, centrifuge the empty tube at 12000rpm for 2 minutes at room temperature. Transfer the RNAPure Columns to a new RNase-free 1.5ml ep tube, and add 100μl enzyme-free double distilled water to the center of the adsorption column. Incubate at room temperature for 2 minutes, and centrifuge at 1200rpm for 1 minute to elute the RNA. The extracted RNA is reverse transcribed for PCR experiments or stored at -80℃.
[0112] qRT-PCR experiments were used to detect the expression levels of adipogenesis-related factors Pparγ, C / ebpα and lipid metabolism-related factors Fabp4, Adipoq, Ldlr, Il-1β and Il-6 in bone tissue of P, G and G+ groups, and Actin was used as control 2 -ΔΔct The relative expression was calculated by Fig.25 shown.
[0113] Depend on Fig.25 It can be seen that compared with the G group, the levels of Pparγ, C / ebpα, Fabp4 and Ldlr in the proximal tibia bone tissue of rats in the G+ group were significantly decreased (P < 0.05), while the expression of Adipoq showed a downward trend, indicating that the small molecule drug AN698 / 40746067 can effectively reduce the expression of adipogenesis-related factors in the bone marrow.
[0114] qRT-PCR experiments were used to detect the expression levels of inflammatory factors Il-1β and Il-6 in bone tissues of the P, G, and G+ groups. Fig.26 shown.
[0115] Depend on Fig.26 It can be seen that a high-fat diet can increase the expression of Il-1β and Il-6 in the bone marrow of mice, while the expression of inflammatory factors in the G+ group after treatment with the small molecule drug AN698 / 40746067 was significantly reduced, indicating that the small molecule drug AN698 / 40746067 can effectively alleviate bone marrow inflammation induced by a high-fat diet.
[0116] Example 12: Effect of AN698 / 40746067 on bone marrow obesity in hyperlipidemic rats
[0117] The decalcified sections of bone tissues of rats in the P, G, and G+ groups were subjected to HE and RUNX2 immunohistochemical staining as follows.
[0118] Preparation of decalcified bone tissue sections: The bone tissue was fixed, rinsed and decalcified with 10% EDTA for 30 days, followed by dehydration, transparency, wax immersion, embedding, sectioning and HE staining. The results are as follows Fig. 27 shown.
[0119] The steps of RUNX2 immunohistochemical staining are as follows: after placing the paraffin sections of bone tissue on a baking machine for 2 hours, they were placed in xylene I and II for transparentization for 5 minutes each; gradient alcohol dehydration: 100% alcohol I → 100% alcohol II → 95% alcohol → 85% alcohol → 75% alcohol, soak for 5 minutes each, and gently soak and rinse with PBS buffer 3 times, each time for 5 minutes; drip 0.1% trypsin digestion solution to cover the tissue, incubate in a wet box at 37°C for 15 minutes, and rinse with PBS 3 times, each time for 5 minutes; drip 3% hydrogen peroxide to cover the tissue, incubate in a wet box at 37°C for 10 minutes, and rinse with PBS 3 times, each time for 5 minutes; drip goat serum to cover the tissue, incubate in a wet box at 37°C for 2 minutes, and discard the old solution; drip diluted R UNX2 antibody, incubate overnight at 4°C in a wet box; place in an oven to return to room temperature, recover RUNX2 primary antibody, gently rinse 3 times with PBS, 5 minutes each time; add diluted secondary antibody (ratio 1:100), incubate in a wet box at 37°C for 20 minutes, discard the secondary antibody in the wet box, rinse 3 times with PBS, 5 minutes each time; absorb excess PBS buffer with absorbent paper, add streptavidin-POD working solution, incubate in a wet box at 37°C for 15 minutes, rinse 3 times with PBS buffer, 5 minutes each time; add DAB working solution and observe under a microscope, discard the staining solution when the staining degree is appropriate, rinse with PBS; stain with hematoxylin for 1-2 seconds, rinse with running water for 4 minutes, rehydrate with gradient alcohol 85%→95%→100%I→100%II for 5 minutes each; xylene I→xylene II are transparent for 5 minutes each, then seal with neutral gum, the results are as follows Fig.28 shown.
[0120] Depend on Figures 27-28 It can be seen that the number of adipocytes in the bone marrow cavity of rats in group G showed bone marrow obesity, while the number and diameter of adipocytes in group G+ treated with small molecule drug AN698 / 40746067 decreased. Immunohistochemistry results showed that treatment with small molecule drug AN698 / 40746067 could alleviate the decrease in the width of the growth plate and the length of the underlying trabeculae in group G, and the expression of RUNX2 was increased.
[0121] Example 13: Effect of AN698 / 40746067 on osteoporosis in hyperlipidemic rats
[0122] Micro-CT detection and analysis were performed on the distal end of the femur of rats in the P, G, and G+ groups. The specific method is as follows.
[0123] The femurs and tibias of three groups of rats were scanned using the Quantum GX2 small animal in vivo Micro-CT imaging system to obtain the cancellous bone, compact bone and microstructure information. The femurs and tibias obtained were fixed in 4% paraformaldehyde for 24-48 hours and placed in a 50ml centrifuge tube containing 100% ethanol. When performing Micro-CT detection, the soft tissues such as muscles and ligaments around the bone tissue were removed as much as possible, and the samples were wrapped with sealing film and fixed in the sample bed for scanning. The specific scanning conditions were set as follows: source voltage 90kV, current 88μA, scanning time 14 minutes, and scanning type High resolution. The data workstation (Shandong University Advanced Medical Research Institute) performed three-dimensional reconstruction, and the region of interest ROI was set to 2.0mm near the distal femoral epiphysis, and bone density (Ct.BMD), bone volume percentage (Ct.BV / TV), and trabecular bone thickness (Tb.N) were measured. Data Viewer software was used to observe the trabeculae and diaphysis of different sections of bone tissue (sagittal, coronal and horizontal planes). Fig.29 shown.
[0124] Depend on Fig.29 It can be seen that the distal femoral cortical bone density (Ct.BMD) and bone volume percentage (Ct.BV / TV) of hyperlipidemic rats were reduced, and the trabecular thickness (Tb.Th) was reduced. After treatment with AN698 / 40746067, the above indicators were restored. Combined with the results of immunohistochemical staining, AN698 / 40746067 alleviated osteoporosis in hyperlipidemic rats.
Claims
1. Application of small molecule drug AN698 / 40746067 in the preparation of a drug for treating hyperlipidemia. The structural formula of the small molecule drug AN698 / 40746067 is shown below:
2. The use according to claim 1, characterized in that The small molecule drug AN698 / 40746067 targets the SDCCAG3 protein and reduces serum lipid levels by inhibiting the adipogenic differentiation of BMSCs.
3. The use according to claim 1, characterized in that The drug for treating hyperlipidemia consists of small molecule drug AN698 / 40746067 and pharmaceutically acceptable excipients.
4. The use according to claim 1, characterized in that The small molecule drug AN698 / 40746067 is used at a concentration of 0.5 to 1.5 mg / kg.
5. Application of small molecule drug AN698 / 40746067 in the preparation of drugs for treating osteoporosis. The structural formula of the small molecule drug AN698 / 40746067 is shown below:
6. The use according to claim 5, characterized in that The osteoporosis is an osteoporosis disease caused by or accompanied by hyperlipidemia.
7. The use according to claim 5, characterized in that The drug for treating osteoporosis consists of small molecule drug AN698 / 40746067 and pharmaceutically acceptable excipients.
8. The use according to claim 5, characterized in that The small molecule drug AN698 / 40746067 is used at a concentration of 0.5 to 1.5 mg / kg.
Citation Information
Patent Citations
Application of cajanolactone A in preparation of medicine used for treating osteoporosis
CN103356607A
Application of PT2399 to preparation of medicine for improving metabolic syndromes
CN109364059A
